



ShareSoc

UK Individual Shareholders Society

5 Liberty Square, Kings Hill,
West Malling, ME19 4AU
Phone: 0333-200-1595
Web: www.sharesoc.org

SHARESOC GROWTH COMPANY SEMINAR

STOCKOPEDIA FINANCIAL ANALYSIS REPORTS ON PRESENTING COMPANIES

(Don't forget ShareSoc subscribing members can get a discount off the Stockopedia service).

Important Note: These reports do not necessarily reflect the latest changes in the financial position of the companies, for example any recent fund raisings, but are primarily based on the last annual financial statements and future forecasts.

Copies of the Powerpoint presentations given by presenters at these seminars are normally added to the ShareSoc Members Network (<http://sharesoc.ning.com>) in a Forum entitled "ShareSoc Growth Company Seminar Reports" soon after the Seminar. Use the site search facility at top right to locate those for a particular company if you cannot find the Forum.

Use the page below and overleaf to take notes on the presentations.

ShareSoc Investment Warning - Company Presentations

No warranty is given by ShareSoc as to the reliability, accuracy or completeness of the information provided in presentations to investors by companies or by ShareSoc representatives in seminars organised or sponsored by ShareSoc. The information given in those seminars is provided for information purposes only and does not constitute investment, legal, tax or other advice or any recommendation to buy, or sell or otherwise transact in the shares of the companies presenting. Prospective investors should take appropriate professional advice before making any investment decision, or undertake their own further research. You are reminded that investment in the stock market carries substantial risks and share prices can go down as well as up. Past performance is not necessarily an indication of future performance.

Angle

AGL  43.9p ▼ -0.6 -1.3%Speculative, Small Cap, **Sucker Stock**

Market Cap

£51.4m

Quality

▲ 33

Enterprise Value

£46.4m

Value

2

Revenue

£467k

Momentum

▼ 21

Market Cap Rank

1146th / 1829

StockRank™

7

Zoom 1m 3m 6m YTD 1y 2y 3y 5y All



Momentum

Relative Strength (%)

1m -13.3% ●

3m -13.5% ●

1yr -13.4% ●

Volume Change (%)

10d v 3m -24.2% ●

Price vs... (%)

52w High -45.1% ●

50d MA -8.36% ●

200d MA -3.31% ●

Growth & Value

vs. industry vs. market

12m Forecast Rolling

PE Ratio (f) n/a

PEG Ratio (f) n/a

EPS Growth (f) n/a %

Dividend Yield (f) n/a %

Valuation (ttm)

Price to Book Value 5.06

Price to Tang. Book 6.43

Price to Free Cashflow n/a

Price to Sales 110.1

EV to EBITDA n/a

Margin of Safety (beta)


Broker Target

15.2%

Relative to Sector

-33%

Screens Passed 1

AGL qualifies for James Montier 'Cooking the Books' S... (in **Short Selling**).[View Screen](#) · [View Checklist](#)

Quality

vs. industry vs. market

Return on Capital -91.5 %

Return on Equity -63.6 %

Operating Margin -1,849 %

Financial Summary


Balance Sheet · Income Statement · Cashflow

Year End 30th Apr		2012	2013	2014	2015	2016	2017	TTM	2018E	2019E	CAGR / Avg
Revenue	£m	1.49	0.97	0.000	0.000	0.36	0.50	0.47	1.10	3.30	-19.7%
Operating Profit	£m	-2.75	-1.07	-2.21	-3.88	-5.45	-7.44	-8.63			
Net Profit	£m	-2.59	-0.87	-1.06	-3.59	-4.89	-6.57	-7.41	-7.28	-7.29	
EPS Reported	p	-7.52	-2.13	-4.49	-7.51	-8.37	-8.95	-9.90			
EPS Normalised	p	-7.42	-1.42	-4.42	-7.15	-8.37	-8.95	-9.90	-6.80	-6.00	
EPS Growth	%										
PE Ratio	x						n/a	n/a	n/a	n/a	
PEG	x						n/a	n/a	n/a	n/a	
Profitability											
Operating Margin	%	-184.3	-110.6			-1,509	-1,493	-1,849			-549.6%
ROA	%		-13.6	-29.6	-41.2	-54.8		-67.4			
ROCE	%	-60.6	-15.5	-40.1	-38.4	-104.1	-84.4	-91.5			-57.2%
ROE	%		-14.8	-31.1	-42.6	-58.0	-84.0	-63.6			-46.1%
Cashflow											
Op. Cashflow ps	p	-3.22	-3.43	-4.39	-6.94	-8.15	-10.1	-10.4			
Capex ps	p	0.046	2.66	0.78	0.90	0.88	0.61	1.27			+67.2%
Free Cashflow ps	p	-3.26	-6.09	-5.17	-7.84	-9.03	-10.7	-11.6			
Dividends											
Dividend ps	p										
Dividend Growth	%										
Dividend Yield	%										
Dividend Cover	x										
Balance Sheet											
Cash etc	£m	1.12	3.43	3.90	8.44	3.76	5.54	4.28			+37.6%
Working Capital	£m	1.36	3.34	3.63	8.52	3.43	6.06	6.43			+34.8%
Net Fixed Assets	£m	2.77	2.50	0.74	0.42	0.46	0.82	0.85			-21.5%
Net Debt	£m	-0.99	-3.30	-3.90	-8.44	-3.76	-5.54	-4.28			
Book Value	£m	4.58	7.10	5.92	10.9	6.12	9.53	10.2			+15.8%
Average Shares	m	34.4	40.6	45.1	47.6	58.9	73.4	73.5			+16.4%
Book Value ps	p	12.1	15.7	13.1	18.4	10.4	12.7	11.8			+1.0%

Health Trend

Piotroski F-Score

3



Bankruptcy Risk

Altman Z1-Score

27.9



Earnings Manipulation Risk

Low

Magic Formula Score

2649 12% E+



Other Ratios

Leverage (ttm)		total	-intang	+pension
Gross Gearing	%			
Net Gearing	%	-42.1	-53.5	-42.1
Cash / Assets	%	38.7		38.7
Liquidity (ttm)		Efficiency (ttm)		
Curr. Ratio	4.97	●	Asset Turnover	0.042
Quick Ratio	4.44	●	Rec's Turnover	0.43
Interest Cov.	100.0	●	Stock Turnover	0.18

Recent History

vs. industry vs. market

Latest interim period (ended 31st Oct '17) vs. prior year

Sales Growth -14.2 %

EPS Growth n/a %


3yr Compound Annual Growth Rate

Sales Growth n/a %


EPS Growth n/a %

DPS Growth n/a %

Graphical History Current Fiscal Year 2018



Broker Forecasts				30th Apr 2018			30th Apr 2019		
Price Target: 1.08 (+1461% above Price)				Net Profit	EPS	DPS	Net Profit	EPS	DPS
Est. Long Term Growth Rate: n/a				(£)	(p)	(p)	(£)	(p)	(p)
Consensus Estimate				-7.28m	-6.80	-	-7.29m	-6.00	-
1m Change				-	-	-	-	-	-
3m Change				-472k	+0.85	-	-422k	+1.30	-



Profile Summary



ANGLE plc is a holding company. The Company's principal activity is undertaken in relation to the commercialization of its Parsortix cell separation system, with deployment in non-invasive cancer diagnostics. The Company is a specialist medical diagnostic company, which offers products for cancer diagnostics and fetal health. Its Parsortix cell separation system uses a microfluidic technology in the form of a one-time use cassette to capture and then harvest circulating tumor cells (CTCs) from blood. The cassette captures CTCs based on their less deformable nature and larger size compared to other blood components. The resulting liquid biopsy (blood test) enables the detection and investigation of mutations in the patient's cancer for personalized cancer care. The harvested CTCs have a range of applications, including diagnosis, prognosis, mutational analysis and drug selection, drug development, assessment of treatment effectiveness and remission monitoring.

Directors: [Andrew Newland](#) (CEO), [Ian Griffiths](#) (FID), [Garth Selvey](#) (NEC) 59, [Brian Howlett](#) (NED), [David Quysner](#) (NID),

No. of Employees: 29

No. of Shareholders: n/a

Last Annual	April 30th, 2017	Sector	Healthcare
Last Interim	October 31st, 2017	Industry	Biotechnology & Medical Research
Incorporated	December 4, 2003	Index	FTSE Aim All Share ,
Public Since	March 17, 2004	Exchange	London Stock Exchange (AIM)
Shares in Issue	117,086,522	Eligible for	an ISA? ☒ a SIPP? ☒
Free Float	90.1m (76.9%)		



Address The Surrey Research Park 10 Nugent Road, GUILDFORD, GU2 7AF, United Kingdom

Web <http://www.angleplc.com/>

Phone +44 1483 685830

Contact ()

Auditors RSM UK Audit LLP

AGLQuote

AGL Share Price GBP **Day's Change**

43.9p **▼ -0.6 -1.3%**

Traded 4:15pm · Minimum 15 min delayed · NMS: 5.00k

Volume

122,726

Bid - Ask

43.0 - 44.8

Low - High

0.0 - 0.0

Spread

410bps

Avg Vol (3m)

139,715

Open - Close

44.5 - 43.9


12m Range

46.5 - 49.5

Beta

0.40

AGL Share Price Performance



Latest AGL News Announcements (delayed)

[More »](#)

3rd May	RCS - Angle PLC - Angle & QIAGEN Poster
19th Apr	RCS - Angle PLC - Parsortix in multiple presentations at AACR
19th Apr	Angle PLC - Breakthrough Research with Parsortix
5th Apr	Angle PLC - First patient enrolled in FDA study
26th Mar	Angle PLC - Price Monitoring Extension

Upcoming AGL Events

Wednesday 25th July, 2018 (Estimate)
Full Year 2018 Angle PLC Earnings Release

Recent ↓

Industry Peer Group	
	Silence Therapeuti... Compare vs AGL
	Creo Medical Compare vs AGL
	Tissue Regenix Compare vs AGL
	Bioventix Compare vs AGL
	Summit Therapeutic... Compare vs AGL
	Verona Pharma Compare vs AGL
	Verseon Compare vs AGL
	Oxford Biodynamics Compare vs AGL

[Healthcare](#) [Biotechnology & Medical Research](#)

Scancell Holdings

SCLP 13.6p ▲ 0.7 5.4%Speculative, Small Cap, **Momentum Trap**

Market Cap

£52.3m

Quality

▼ 14

Enterprise Value

£47.3m

Value

6

Revenue

£n/a

Momentum

69

Market Cap Rank

1139th / 1829

StockRank™**18**Zoom 1m 3m 6m YTD **1y** 2y 3y 5y All**Momentum**

Relative Strength (%)

1m -11.1% ●3m -3.6% ●1yr +16.7% ●

Volume Change (%)

10d v 3m -32.4% ●

Price vs... (%)

52w High -30.0% ●50d MA -4.66% ●200d MA +6.31% ●**Growth & Value**

vs. industry vs. market

12m Forecast Rolling

PE Ratio (f) n/a

PEG Ratio (f) n/a

EPS Growth (f) n/a %

Dividend Yield (f) n/a %

Valuation (ttm)

Price to Book Value 5.68

Price to Tang. Book 9.03

Price to Free Cashflow n/a

Price to Sales n/a

EV to EBITDA n/a

Quality

vs. industry vs. market

Return on Capital -52.4 %


Return on Equity -44.0 %

Operating Margin n/a %

Health Trend

Piotroski F-Score

2

**Bankruptcy Risk**

Altman Z2-Score

111.2

**Earnings Manipulation Risk**

N/A

Magic Formula Score

2587 15% E+

**Other Ratios**

Leverage (ttm)	total	-intang	+pension
Gross Gearing	%		
Net Gearing	%	-53.9	-53.9
Cash / Assets	%	51.3	51.3

Liquidity (ttm)	Efficiency (ttm)
Curr. Ratio	13.1 ● Asset Turnover
Quick Ratio	13.1 ● Rec's Turnover
Interest Cov.	-1,977 ● Stock Turnover

Recent History

vs. industry vs. market

Latest interim period (ended 31st Oct '17) vs. prior year

Sales Growth n/a %

EPS Growth n/a %

3yr Compound Annual Growth Rate

Sales Growth n/a %

EPS Growth n/a %

DPS Growth n/a %

Margin of Safety (beta)

Relative to Sector

-40%

Stability Value (EPV)

-90%


Screens Passed

SCLP doesn't qualify for any screens.


Find out why: [View Checklists](#)**Financial Summary**

Balance Sheet · Income Statement · Cashflow

Year End 30th Apr		2012	2013	2014	2015	2016	2017	TTM	2018E	2019E	CAGR / Avg
Revenue	£m	0.000	0.000	0.000	0.000	0.000	0.000	0.000			
Operating Profit	£m	-1.96	-2.18	-2.50	-2.96	-3.04	-4.55	-4.83			
Net Profit	£m	0.56	-1.90	-2.22	-2.41	-2.58	-3.54	-3.85	-4.40	-4.40	
EPS Reported	p	-1.01	-0.95	-1.02	-1.07	-1.13	-1.35	-1.35			
EPS Normalised	p	-1.01	-0.95	-1.02	-1.07	-1.13	-1.35	-1.35	-1.40	-2.09	
EPS Growth	%										
PE Ratio	x						n/a	n/a	n/a	n/a	
PEG	x						n/a	n/a	n/a	n/a	
Profitability											
Operating Margin	%										
ROA	%		-30.0	-29.6	-28.5	-28.8		-46.1			
ROCE	%	-28.1	-42.9	-27.5	-43.8	-30.5	-70.0	-52.4			-40.5%
ROE	%		-31.5	-31.4	-30.5	-30.9	-43.0	-44.0			-33.5%
Cashflow											
Op. Cashflow ps	p	0.45	-1.00	-0.96	-1.17	-1.02	-1.47	-1.47			
Capex ps	p	0.023	0.035	0.011	0.000	0.000	0.023	0.002			+0.6%
Free Cashflow ps	p	0.43	-1.03	-0.97	-1.17	-1.02	-1.49	-1.47			
Dividends											
Dividend ps	p										
Dividend Growth	%										
Dividend Yield	%										
Dividend Cover	x										
Balance Sheet											
Cash etc	£m	3.53	1.49	5.57	3.06	6.53	2.67	4.96			-5.4%
Working Capital	£m	3.45	1.55	5.55	3.25	6.51	2.99	5.71			-2.8%
Net Fixed Assets	£m	0.11	0.13	0.12	0.087	0.065	0.093	0.081			-2.6%
Net Debt	£m	-3.53	-1.49	-5.57	-3.06	-6.53	-2.67	-4.96			
Book Value	£m	6.97	5.09	9.08	6.75	9.99	6.50	9.21			-1.4%
Average Shares	m	191.9	200.4	218	226.3	228.2	262.3	286.7			+6.5%
Book Value ps	p	3.48	2.54	4.01	2.98	3.81	2.48	2.94			-6.6%

Graphical History Current Fiscal Year 2018

Broker Forecasts			30th Apr 2018			30th Apr 2019		
Price Target: N/A			Net Profit	EPS	DPS	Net Profit	EPS	DPS
Est. Long Term Growth Rate: n/a			(£)	(p)	(p)	(£)	(p)	(p)
Consensus Estimate			-4.40m	-1.40	-	-4.40m	-2.09	-
1m Change			+1.13m	+0.16	-	+2.70m	-	-
3m Change			+1.13m	+0.16	-	+2.70m	-	-



Profile Summary




Scancell Holdings plc is a biopharmaceutical company focused on the cancer therapeutics market. The Company's principal activity consists of the discovery and development of monoclonal antibodies and vaccines for the treatment of cancer. The Company is developing a pipeline of immunotherapies for the treatment of cancer based on its ImmunoBody and Moditope platforms. The Company's products include SCIB1, SCIB2 and Modi-1. The Company's first cancer vaccine, SCIB1, is being developed for the treatment of melanoma and is in Phase I/II clinical trials. SCIB2 contains multiple T cell epitopes derived from the lung cancer associated antigen NY-ESO-1. It is developed to the point at which the product is defined and ready for further preclinical development as an immunotherapy for any tumor that expresses the NY-ESO-1 antigen. The Company's first Moditope development candidate is Modi-1. Modi-1 consists of two citrullinated vimentin peptides and one citrullinated enolase peptide.

Directors: [Clifford Holloway](#) (CEO) 57, [Lindy Durrant](#) (CSO), [Richard Goodfellow](#) (EDR), [Sally Adams](#) (OTH) 54, [John Chiplin](#) (NEC) 57, [Katherine Cornish-Bowden](#) (NED) 44, [Matthew Frohn](#) (NED), [Alan Lewis](#) (NED) 71,

No. of Employees: 14

No. of Shareholders: n/a

Last Annual	April 30th, 2017	Sector	Healthcare
Last Interim	October 31st, 2017	Industry	Biotechnology & Medical Research
Incorporated	April 14, 2008	Index	FTSE Aim All Share ,
Shares in Issue	384,611,936	Exchange	London Stock Exchange (AIM)
Free Float	334.5m (87.0%)	Eligible for	an ISA? a SIPP?



Address Department of Clinical Oncology, Hucknall Road, NOTTINGHAM, NG5 1PB, United Kingdom

Web <http://www.scancell.co.uk/>

Phone +44 115 8231863

Auditors Champion Accountants LLP

SCLPQuote

SCLP Share Price
GBP

13.6p

Traded 4:18pm · Minimum 15 min delayed · NMS: 10.00k

Day's Change

▲ 0.7 5.4%

Volume

471,608

Avg Vol (3m)

548,475

Bid - Ask

13.2 - 14.0

Open - Close

13.2 - 13.6

Low - High

0.0 - 0.0

12m Range

10.5 - 16.6


Spread

588bps

Beta

-0.92

SCLP Share Price Performance



Latest SCLP News Announcements (delayed)

[More »](#)

Fri 1:11pm	Scancell Hlds Legal & General Grp - Holding(s) in Company
Wed 10:12am	Scancell Hlds - Holding(s) in Company
Tue 7:00am	Scancell Hlds - Result of the Open Offer and PDMR Shareholdings
23rd Apr	Scancell Hlds Hygea VCT plc - Holding(s) in Company
20th Apr	Scancell Hlds - Holding(s) in Company

Upcoming SCLP Events

Recent ↓

Industry Peer Group

	Silence Therapeuti...	☐
	Compare vs SCLP	
	Creo Medical	☐
	Compare vs SCLP	
	Tissue Regenix	☐
	Compare vs SCLP	
	Bioventix	☐
	Compare vs SCLP	
	Summit Therapeutic...	☐
	Compare vs SCLP	
	Verona Pharma	☐
	Compare vs SCLP	
	Verseon	☐
	Compare vs SCLP	
	Oxford Biodynamics	☐
	Compare vs SCLP	

Healthcare

Biotechnology & Medical Research

Evgen Pharma

EVG  17.75p  0.0 0.0%Highly Speculative, Micro Cap, **Sucker Stock**

Market Cap	£16.6m	Quality	9
Enterprise Value	£14.3m	Value	2
Revenue	£n/a	Momentum	20
Market Cap Rank	1438th / 1829	StockRank™	2

Zoom 1m 3m 6m YTD 1y 2y 3y 5y All



Momentum

Relative Strength (%)

1m +31.6% ●

3m +28.4% ●

1yr -11.8% ●

Volume Change (%)

10d v 3m +195% ●

Price vs... (%)

52w High -39.3% ●

50d MA +22.7% ●

200d MA +10.9% ●

Growth & Value


12m Forecast Rolling

PE Ratio (f) n/a  PEG Ratio (f) n/a  EPS Growth (f) n/a %  Dividend Yield (f) n/a %  

Valuation (ttm)

Price to Book Value 6.29  Price to Tang. Book 6.59  Price to Free Cashflow n/a  Price to Sales n/a  EV to EBITDA n/a  

Margin of Safety (beta)



Screens Passed

EVG doesn't qualify for any screens.
Find out why: [View Checklists](#)

Quality

Return on Capital -138.5 %  Return on Equity -75.3 %  Operating Margin n/a %  

Financial Summary


Balance Sheet · Income Statement · Cashflow

Year End 31st Mar		2012	2013	2014	2015	2016	2017	TTM	2018E	2019E	CAGR / Avg
Revenue	£m	0.000	0.000	0.000	0.000	0.000	0.000	0.000			
Operating Profit	£m	0.000	-0.95	-0.96	-1.25	-2.43	-3.66	-3.65			
Net Profit	£m	0.000	-0.87	-1.08	-2.27	-3.13	-3.07	-3.06	-3.56	-4.61	
EPS Reported	p	0.000	-1.19	-1.48	-3.12	-6.29	-4.19	-4.18			
EPS Normalised	p	0.000	-1.19	-1.48	-2.86	-5.40	-4.19	-4.18	-4.56	-4.98	
EPS Growth	%										
PE Ratio	x						n/a	n/a	n/a	n/a	
PEG	x						n/a	n/a	n/a	n/a	
Profitability											
Operating Margin	%										
ROA	%		-558.7	-245.9	-493.1	-80.8		-79.2			
ROCE	%		-538.1	-254.5		-34.3	-86.5	-138.5			-182.7%
ROE	%		-984.1	-603.4		-106.2	-54.2	-75.3			-349.6%
Cashflow											
Op. Cashflow ps	p	0.000	-1.07	-1.09	-1.24	-3.13	-4.36	-4.58			
Capex ps	p	0.000	0.047	0.000	0.001	0.084	0.10	0.016			+22.2%
Free Cashflow ps	p	0.000	-1.11	-1.09	-1.24	-3.22	-4.47	-4.59			
Dividends											
Dividend ps	p										
Dividend Growth	%										
Dividend Yield	%										
Dividend Cover	x										
Balance Sheet											
Cash etc	£m	0.000	0.11	0.31	0.16	7.13	3.86	2.21			+141.7%
Working Capital	£m	n/a	0.12	0.32	-0.17	7.01	4.09	2.50			+143.7%
Net Fixed Assets	£m	0.000	0.002	0.001	0.001	0.006	0.011	0.015			+53.1%
Net Debt	£m	0.000	-0.11	-0.16	0.90	-7.13	-3.86	-2.21			
Book Value	£m	0.000	0.18	0.18	-1.19	7.09	4.23	2.63			+121.4%
Average Shares	m	0.000	72.9	72.9	72.9	49.8	73.2	73.3			+0.10%
Book Value ps	p	0.000	0.24	0.25	-1.63	9.69	5.77	3.55			+121.1%

Health Trend

Piotroski F-Score 

2



Bankruptcy Risk

Altman Z2-Score 

37.0



Earnings Manipulation Risk

N/A

Magic Formula Score

2788 5% E-




Other Ratios

Leverage (ttm)		total	-intang	+pension
Gross Gearing	%			
Net Gearing	%	-83.8	-87.8	-83.8
Cash / Assets	%	73.8		73.8
Liquidity (ttm)		Efficiency (ttm)		
Curr. Ratio	7.98 ●	Asset Turnover	n/a	
Quick Ratio	7.98 ●	Rec's Turnover	n/a	
Interest Cov.	100.0 ●	Stock Turnover	n/a	


Recent History

Latest interim period (ended 30th Sep '17) vs. prior year			
Sales Growth	n/a	%	 
EPS Growth	n/a	%	 
3yr Compound Annual Growth Rate			
Sales Growth	n/a	%	 
EPS Growth	n/a	%	 
DPS Growth	n/a	%	 

Graphical History Current Fiscal Year 2018



Broker Forecasts			31st Mar 2018			31st Mar 2019		
Price Target: 0.97 (+446.51% above Price)			Net Profit	EPS	DPS	Net Profit	EPS	DPS
Est. Long Term Growth Rate: n/a			(£)	(p)	(p)	(£)	(p)	(p)
Consensus Estimate			-3.56m	-4.56	-	-4.61m	-4.98	-
1m Change			-	-	-	-	-	-
3m Change			-	-	-	-	-	-



Profile Summary

evgen pharma


Evgen Pharma plc is a clinical-stage drug development company focused on cancer and neurological disease. The Company operates through the segment of development of pharmaceutical products all within the United Kingdom. Its pipeline is based on its Sulforadex technology and includes various synthetic, stabilized analogues of the naturally occurring compound sulforaphane. Its pipeline includes SFX-01: breast cancer; SFX-01: subarachnoid hemorrhage, and other programs. The objective of SFX-01 therapy is to reduce the number of cancer stem cells (CSCs) proliferating in tumors treated with anti-hormonal agents and prolong the duration of response. The objective of SFX-01 therapy (co-administered with standard-of-care nimodipine) is to reduce the vasospasm and incidence of delayed cerebral ischemia in the days following the hemorrhage. It has a preclinical SFX-01 program in multiple sclerosis and a clinical interest in prostate cancer.

Directors: [Barry Clare \(CHM\) 62](#), [Stephen Franklin \(CEO\) 47](#), [Richard Moulson \(CFO\)](#), [Hamina Patel \(OTH\)](#), [Alan Barge \(NED\) 58](#), [Marc D'Abbadie \(NED\)](#), [Sue Foden \(NED\) 62](#),

No. of Employees: 2

No. of Shareholders: n/a

Last Annual	March 31st, 2017	Sector	Healthcare
Last Interim	September 30th, 2017	Industry	Biotechnology & Medical Research
Incorporated	October 2, 2014	Index	FTSE Aim All Share ,
Public Since	October 21, 2015	Exchange	London Stock Exchange (AIM)
Shares in Issue	93,276,858	Eligible for	an ISA? a SIPP?
Free Float	74.4m (79.7%)		



Address The Colony,146 Brownlow Hill
Altrincham Road, WILMSLOW, SK9 4LY,
United Kingdom

Web <http://evgen.com/>

Phone +44 151 7053532

Contact ()

Auditors RSM UK Audit LLP

EVGQuote				EVG Share Price Performance			
EVG Share Price GBP	Day's Change	Volume	Bid - Ask	Low - High	Spread	1 year 1 week	
17.75p	0.0 0.0%	89,058	17.0 - 18.5	0.0 - 0.0	845bps		
Traded 3:02pm · Minimum 15 min delayed · NMS: 3.00k		Avg Vol (3m)	Open - Close	12m Range	Beta	-25% 0% 25% 50%	
		296,248	17.8 - 17.8	12.8 - 21.0	0.00		

Latest EVG News Announcements <i>(delayed)</i>		More »
2nd May	Evgen Pharma PLC - Grant of further European patent	
26th Apr	Evgen Pharma PLC - Second Price Monitoring Extn	
26th Apr	Evgen Pharma PLC - Price Monitoring Extension	
24th Apr	Evgen Pharma PLC - Presentation at World Orphan Drug Congress USA	
20th Mar	BRIEF-Evgen Pharma Says New Research Collaboration With Imperial College London	

Upcoming EVG Events
Recent ↓

Industry Peer Group	
	Silence Therapeuti... Compare vs EVG
	Creo Medical Compare vs EVG
	Tissue Regenix Compare vs EVG
	Bioventix Compare vs EVG
	Summit Therapeutic... Compare vs EVG
	Verona Pharma Compare vs EVG
	Verseon Compare vs EVG
	Oxford Biodynamics Compare vs EVG